GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome

Abstract Background and Aim Wolfram syndrome (WS) is a rare autosomal disorder caused by WFS1 gene mutations, currently lacking approved treatments. Preclinical and clinical reports suggest that diabetes medications, such as glucagon-like peptide-1 receptor agonist (GLP1-RA), slow WS-related diabete...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Toomas Jagomäe, Sandra Velling, Tessa Britt Tikva, Varvara Maksimtšuk, Nayana Gaur, Riin Reimets, Allen Kaasik, Eero Vasar, Mario Plaas
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-03-01
coleção:	Diabetology & Metabolic Syndrome
Assuntos:	Wolfram syndrome Wfs1 GABA GLP1-RA Liraglutide Langerhans islet
Acesso em linha:	https://doi.org/10.1186/s13098-025-01651-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!